Treatment and Management of Myasthenia Gravis in Adults
Myasthenia gravis (MG), an intractable disease characterized by the production of autoantibodies against neuromuscular junction proteins, causes generalized muscle weakness. Treatment usually includes administration of steroids and immunosuppressants; however, it is difficult to achieve remission. Disease suppression and achieving the treatment goal in the early stages of MG may lead to improved long-term prognosis. In cases refractory to conventional treatments, early institution of fast-acting treatment, including intravenously administered high-dose methylprednisolone and biological treatments, is important to suppress disease activity. Following the availability of a variety of treatments and the increasing incidence of MG in the aging population, the scenario of MG treatments has changed significantly. In this study, we review the various treatment strategies and management of MG in adults.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Brain and nerve = Shinkei kenkyu no shinpo - 76(2024), 1 vom: 06. Jan., Seite 13-18 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Uzawa, Akiyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 10.01.2024 Date Revised 10.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11477/mf.1416202552 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366817396 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366817396 | ||
| 003 | DE-627 | ||
| 005 | 20240114233537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11477/mf.1416202552 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM366817396 | ||
| 035 | |a (NLM)38191134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Uzawa, Akiyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment and Management of Myasthenia Gravis in Adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2024 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Myasthenia gravis (MG), an intractable disease characterized by the production of autoantibodies against neuromuscular junction proteins, causes generalized muscle weakness. Treatment usually includes administration of steroids and immunosuppressants; however, it is difficult to achieve remission. Disease suppression and achieving the treatment goal in the early stages of MG may lead to improved long-term prognosis. In cases refractory to conventional treatments, early institution of fast-acting treatment, including intravenously administered high-dose methylprednisolone and biological treatments, is important to suppress disease activity. Following the availability of a variety of treatments and the increasing incidence of MG in the aging population, the scenario of MG treatments has changed significantly. In this study, we review the various treatment strategies and management of MG in adults | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Brain and nerve = Shinkei kenkyu no shinpo |d 2007 |g 76(2024), 1 vom: 06. Jan., Seite 13-18 |w (DE-627)NLM168920336 |x 1881-6096 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2024 |g number:1 |g day:06 |g month:01 |g pages:13-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11477/mf.1416202552 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2024 |e 1 |b 06 |c 01 |h 13-18 | ||